Savella generic
Savella is an anti-fibromyalgia drug owned by Allergan. Its active ingredient, milnacipran hydrochloride, was first authorised for market use on 14 January 2009. The drug is available in tablet form for oral consumption. Savella has a total of 2 drug patents; one of these has already expired.
When will Savella generic be available?
The generic version of Savella can potentially be released after 19 September, 2029, when the last patent (US7994220) titled 'Milnacipran for the long-term treatment of fibromyalgia syndrome' expires. The earlier patent (US6602911), titled 'Methods of treating fibromyalgia', expired on 14 January 2023.
Savella uses
Savella is primarily used in the management of fibromyalgia. milnacipran hydrochloride, the active ingredient in Savella, works by increasing the levels of serotonin and norepinephrine in the brain to help maintain mental balance and stop the transmission of pain signals in the brain.
Savella patent expiration
Savella's generic won't be available until the final patent, 'Milnacipran for the long-term treatment of fibromyalgia syndrome', expires on September 19, 2029. The earlier patent titled 'Methods of treating fibromyalgia' expired on January 14, 2023. Below are the details of the patent: